As per file enclosed

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.1%Reaction day

₹1160.00

prior close

₹1219.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.0%+5.1% vs market

Pharmaceuticals peers, median of 164sector+0.1%+5.0% vs sector

On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.1-0.0+5.1+0.1+5.0

Next day

+10.3-0.7+11.0-0.6+10.9

+15.9-1.8+17.6-1.3+17.2

+21.7-0.7+22.4-1.4+23.1

+27.7-0.5+28.2-1.6+29.3

+34.1+0.4+33.7-0.6+34.7

+41.9-1.6+43.5-2.3+44.2

15d

+48.5+4.6+43.9+0.0+48.5

+66.3+4.6+61.7+3.0+63.3

+35.6+6.1+29.4+4.3+31.3

+37.9+10.8+27.1+8.6+29.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies Ltd reported strong FY2026 results with standalone revenue from operations of Rs 768.73 Cr, up 19.3% from Rs 644.47 Cr in FY2025. Net profit jumped 89% to Rs 99.31 Cr from Rs 52.55 Cr, while EPS grew to Rs 74.29 from Rs 39.32. Consolidated net profit was even stronger at Rs 102.78 Cr, up 127% YoY. EBITDA stood at Rs 155.37 Cr with positive operating cash flow of Rs 151.09 Cr. The board has recommended a final dividend of Rs 10 per share (100% on face value Rs 10), payable after shareholder approval at the 37th AGM on August 20, 2026. The statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated results. The company operates only in the pharmaceuticals segment with subsidiaries in Germany and Hungary.

Likely market impact

The company delivered robust double-digit growth in both revenue and profit, exceeding 20% revenue growth and showing exceptional 89-127% profit growth. The clean audit opinion and proposed 100% dividend are positive signals for shareholders. The stock is likely to react positively to these results.

By the numbersConsolidated · Q4 FY26 vs Q4 FY25

	Q4 FY26	Q4 FY25	Change
Revenue	₹259.4 Cr	₹195.0 Cr	+33.0%
Operating profit	₹56.65 Cr	₹24.28 Cr	+133.3%
Profit after tax	₹47.49 Cr	₹21.00 Cr	+126.1%
EBITDA margin	24.4%	14.9%	+9.6 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.